PT-141 Dosage & Reconstitution Guide
Reconstitution math, syringe draw reference, and dosing protocols — everything in one place.
What Is PT-141?
PT-141 (Bremelanotide) is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is FDA-approved under the brand name Vyleesi for the treatment of acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered via a pre-filled autoinjector. Research-grade PT-141 exists in a separate market and is not FDA-approved as a general-use compound. This guide covers reconstitution and dosing math for lyophilized research-grade PT-141 only.
PT-141 works through melanocortin receptor activation, a mechanism distinct from traditional erectile dysfunction medications, which has driven research interest in its effects on sexual arousal pathways in both research literature and the broader research community.
This guide is for research purposes only and does not apply to the FDA-approved pharmaceutical product Vyleesi, which is available by prescription and comes pre-formulated in an autoinjector.
Common Research Doses
| Research application | Dose range | Frequency |
|---|---|---|
| Standard research protocol | 1.0–2.0 mg | As needed, not to exceed once in 24 hours |
| Lower range | 0.5–1.0 mg | As needed |
PT-141 is dosed in milligrams (mg). Most research protocols use as-needed dosing rather than a fixed daily schedule, typically administered 45 minutes to several hours before the desired window of effect.
Most research protocols limit use to no more than 8 doses per month based on patterns observed with the FDA-approved product labeling.
Reconstitution Reference
| Vial size | BAC water | Concentration | Doses at 1.0 mg | Doses at 2.0 mg |
|---|---|---|---|---|
| 10 mg | 2.0 mL | 5.0 mg/mL | 10 | 5 |
| 10 mg | 1.0 mL | 10.0 mg/mL | 10 | 5 |
| 20 mg | 2.0 mL | 10.0 mg/mL | 20 | 10 |
Calculate your exact syringe draw
Open the Calculator →Syringe Draw Reference
| Dose | Draw to |
|---|---|
| 0.5 mg | 10 units |
| 1.0 mg | 20 units |
| 2.0 mg | 40 units |
| Dose | Draw to |
|---|---|
| 0.5 mg | 5 units |
| 1.0 mg | 10 units |
| 2.0 mg | 20 units |
Side Effects Commonly Reported
The most commonly reported effects associated with PT-141 in research and clinical literature include transient nausea, flushing, and headache. Nausea is most pronounced at higher doses and tends to diminish with repeated use. Some research has also noted transient increases in blood pressure following administration — this is a known effect of melanocortin receptor activation and is a key reason dosing frequency is typically limited.
PT-141 is not recommended for use in individuals with uncontrolled hypertension or cardiovascular disease due to its effects on blood pressure. This is a research consideration, not medical advice — consult a healthcare professional regarding any cardiovascular risk factors.
Sourcing
Recommended Supplier
PSPeptides carries third-party tested, research-grade PT-141 with published COAs.
Discount Code: BANANAS10
Website: pspeptides.com/?ref=bananas
Shop PSPeptides →Affiliate disclosure: The Protocol Kit earns a commission from qualifying purchases at no additional cost to you.